Literature DB >> 11679928

Opsonic phagocytosis of Streptococcus pneumoniae by alveolar macrophages is not impaired in human immunodeficiency virus-infected Malawian adults.

S B Gordon1, M E Molyneux, M J Boeree, S Kanyanda, M Chaponda, S B Squire, R C Read.   

Abstract

Streptococcus pneumoniae is a major cause of pneumonia, bacteremia, and meningitis, especially among adults infected with the human immunodeficiency virus (HIV). Alveolar macrophages (AMs) are critical components of cellular defense against bacterial infection and are both infected and affected by HIV. In this study, AMs obtained at bronchoscopy from 44 Malawian adults (24 HIV positive and 20 HIV negative) were exposed in vitro to opsonized S. pneumoniae and coagulase-negative staphylococci. AMs from HIV-positive and -negative volunteers showed no significant difference in binding to or internalization of either S. pneumoniae or coagulase-negative staphylococci. In HIV-positive subjects, the presence of detectable HIV in lung fluid was not associated with AM impairment. AMs from HIV-infected adults did not exhibit impaired pneumococcal phagocytosis in the assay used. This suggests that an alternative mechanism of susceptibility is operating in these individuals.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11679928     DOI: 10.1086/324080

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  13 in total

Review 1.  The complexity of HIV persistence and pathogenesis in the lung under antiretroviral therapy: challenges beyond AIDS.

Authors:  Sharilyn Almodovar
Journal:  Viral Immunol       Date:  2014-05-05       Impact factor: 2.257

Review 2.  Hidden risks for pneumonia in Malawi.

Authors:  D G Fullerton; S B Gordon
Journal:  Malawi Med J       Date:  2003-06       Impact factor: 0.875

3.  Macrophages Are Phenotypically and Functionally Diverse across Tissues in Simian Immunodeficiency Virus-Infected and Uninfected Asian Macaques.

Authors:  Alexandra M Ortiz; Sarah R DiNapoli; Jason M Brenchley
Journal:  J Virol       Date:  2015-03-18       Impact factor: 5.103

4.  HIV gp120 in the Lungs of Antiretroviral Therapy-treated Individuals Impairs Alveolar Macrophage Responses to Pneumococci.

Authors:  Paul J Collini; Martin A Bewley; Mohamed Mohasin; Helen M Marriott; Robert F Miller; Anna-Maria Geretti; Apostolos Beloukas; Athanasios Papadimitropoulos; Robert C Read; Mahdad Noursadeghi; David H Dockrell
Journal:  Am J Respir Crit Care Med       Date:  2018-06-15       Impact factor: 21.405

Review 5.  An official ATS workshop report: Emerging issues and current controversies in HIV-associated pulmonary diseases.

Authors:  Alison Morris; Kristina Crothers; James M Beck; Laurence Huang
Journal:  Proc Am Thorac Soc       Date:  2011-03

6.  Modulation of host microtubule dynamics by pathogenic bacteria.

Authors:  Girish K Radhakrishnan; Gary A Splitter
Journal:  Biomol Concepts       Date:  2012-12-01

Review 7.  Impact of antiretroviral therapy on lung immunology and inflammation.

Authors:  Homer L Twigg; Kenneth S Knox
Journal:  Clin Chest Med       Date:  2013-04-08       Impact factor: 2.878

8.  HIV-Related Lung Disorders.

Authors:  Homer L Twigg; Kenneth S Knox
Journal:  Drug Discov Today Dis Mech       Date:  2007

9.  The alveolar microenvironment of patients infected with human immunodeficiency virus does not modify alveolar macrophage interactions with Streptococcus pneumoniae.

Authors:  Stephen B Gordon; R Thomas Jagoe; Elizabeth R Jarman; James C North; Alison Pridmore; Janelisa Musaya; Neil French; Eduard E Zijlstra; Malcolm E Molyneux; Robert C Read
Journal:  Clin Vaccine Immunol       Date:  2013-04-10

10.  Inhaled delivery of 23-valent pneumococcal polysaccharide vaccine does not result in enhanced pulmonary mucosal immunoglobulin responses.

Authors:  Stephen B Gordon; Rose Malamba; Neema Mthunthama; Elizabeth R Jarman; Kondwani Jambo; Khuzwayo Jere; Eduard E Zijlstra; Malcolm E Molyneux; John Dennis; Neil French
Journal:  Vaccine       Date:  2008-08-15       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.